3.3 Hereditary Cancer Syndromes & Genetic Evaluation

Approximately 5% to 10% of all breast cancers are directly attributable to inherited, high-penetrance germline mutations, with an additional 10% to 15% exhibiting familial clustering driven by moderate-penetrance genes and shared environmental factors. Recognizing hereditary cancer syndromes allows breast care nurses to intercept malignancies at early, highly curable stages and implement lifesaving risk-reduction measures for patients and their biological relatives.

Hereditary Breast and Ovarian Cancer (HBOC) Syndrome

Hereditary Breast and Ovarian Cancer (HBOC) syndrome represents the vast majority of identifiable hereditary breast malignancies, primarily caused by autosomal dominant germline pathogenic variants in the tumor suppressor genes BRCA1 and BRCA2.

Molecular Pathophysiology

• DNA Repair Machinery: BRCA1 (located on chromosome 17q21) and BRCA2 (located on chromosome 13q12) encode large nuclear proteins critical for the repair of complex DNA double-strand breaks (DSBs). They function through homologous recombination repair (HRR), a high-fidelity, error-free repair pathway that utilizes the sister chromatid as a template during the S and G2 phases of the cell cycle.
• Genomic Instability: In cells with loss of heterozygosity (loss of the remaining functional wild-type allele), homologous recombination fails. The cell is forced to rely on low-fidelity, error-prone repair mechanisms, such as non-homologous end joining (NHEJ) and single-strand annealing, leading to gross chromosomal translocations, rapid accumulation of mutations, and malignant transformation.

Penetrance and Clinical Phenotypes

Histopathologic Characteristics

• BRCA1 Tumors: Characteristically present as high-grade invasive ductal carcinomas with prominent lymphocytic infiltrate and pushing borders. Over 70% exhibit a triple-negative phenotype (estrogen receptor [ER] negative, progesterone receptor [PR] negative, and HER2 negative) expressing basal markers such as cytokeratin 5/6 and EGFR.
• BRCA2 Tumors: Morphologically and immunophenotypically resemble sporadic breast carcinomas; they are predominantly ER-positive and PR-positive, presenting across standard histological grades.

---

High-Penetrance Non-BRCA Hereditary Syndromes

Several rare, high-penetrance genetic syndromes significantly elevate breast cancer risk alongside distinctive extra-mammary neoplasms.

Li-Fraumeni Syndrome (TP53 Gene)

• Pathophysiology: Caused by heterozygous germline mutations in the TP53 tumor suppressor gene on chromosome 17p13, which encodes the p53 cellular transcription factor ("the guardian of the genome"). Loss of p53 eliminates the G1/S cell-cycle DNA damage checkpoint and impairs apoptosis.
• Malignancy Spectrum: Breast cancer is the most common cancer in female carriers, with a cumulative risk of roughly 50% to 60% by age 70 (overall cancer risk in women approaches 90%) and a median age of onset in the early 30s. Tumors are frequently ER/PR-positive and HER2-positive. Other pathognomonic malignancies include soft tissue and bone sarcomas (osteosarcoma, rhabdomyosarcoma), brain tumors (gliomas, choroid plexus carcinomas), adrenocortical carcinoma (ACC), and acute leukemias.
• Clinical Mandate: Therapeutic and diagnostic ionizing radiation must be strictly avoided when possible because radiation directly triggers secondary radio-induced malignancies in TP53 mutation carriers. Annual whole-body MRI and dedicated brain/breast MRI represent the standard surveillance protocol.

Cowden Syndrome / PTEN Hamartoma Tumor Syndrome (PTEN Gene)

• Pathophysiology: Autosomal dominant mutations in the PTEN gene on chromosome 10q23, which functions as a lipid phosphatase negatively regulating the pro-survival PI3K/AKT/mTOR signaling cascade.
• Clinical Hallmarks: Pathognomonic mucocutaneous lesions (facial trichilemmomas, oral mucosal papillomatosis, acral keratoses), macrocephaly (occipitofrontal circumference ≥97th percentile), cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease), and multiple hamartomatous gastrointestinal polyps.
• Malignancy Spectrum: Lifetime breast cancer risk is 85% (often bilateral), with an average diagnosis between 38 and 46 years. Also confers a 35% lifetime risk of epithelial thyroid cancer (predominantly follicular variant), 28% risk of endometrial adenocarcinoma, 15% risk of renal cell carcinoma, 9% risk of colorectal cancer, and elevated melanoma risk.

Peutz-Jeghers Syndrome (STK11 Gene)

• Pathophysiology: Germline mutations in the STK11/LKB1 serine/threonine kinase gene on chromosome 19p13, which regulates cellular energy metabolism via the AMPK pathway.
• Clinical Hallmarks: Melanocytic mucocutaneous hyperpigmentation (macules on vermilion border of lips, perioral skin, buccal mucosa, hands, and feet) and benign hamartomatous polyposis throughout the gastrointestinal tract, frequently causing intussusception and bowel obstruction.
• Malignancy Spectrum: Lifetime breast cancer risk ranges from 32% to 54% (mean age 37 years). Patients face significant lifetime risks of gastrointestinal cancers (colorectal 39%, gastric 29%, small bowel 13%, pancreatic 11% to 36%), ovarian sex cord tumors with annular tubules (SCTAT), and cervical adenoma malignum.

Hereditary Diffuse Gastric Cancer (CDH1 Gene)

• Pathophysiology: Autosomal dominant mutations in the CDH1 gene on chromosome 16q22, encoding the calcium-dependent cell-cell adhesion glycoprotein E-cadherin.
• Malignancy Spectrum: Confers a 70% to 80% lifetime risk of diffuse (signet-ring cell) gastric adenocarcinoma in men and 56% to 83% in women, typically prompting prophylactic total gastrectomy in early adulthood. In women, CDH1 mutations confer a 40% to 60% lifetime risk of invasive lobular carcinoma (ILC) of the breast. Due to the diffuse, single-file infiltrative growth pattern of ILC, conventional mammography has high false-negative rates; annual screening breast MRI with contrast is vital.

---

Moderate-Penetrance Breast Cancer Susceptibility Genes

Multigene next-generation sequencing (NGS) panels routinely identify pathogenic variants in moderate-penetrance genes that confer a 2- to 4-fold elevation in breast cancer risk (lifetime risk approximately 20% to 50%).

• PALB2 (Partner and Localizer of BRCA2): Functions as the physical scaffold anchoring BRCA2 to BRCA1 during homologous recombination. Pathogenic PALB2 variants confer a lifetime breast cancer risk of 40% to 60%, a risk profile approaching that of BRCA2. Carriers also exhibit elevated risks of pancreatic and male breast cancer. NCCN guidelines recommend high-risk screening (annual mammography plus annual breast MRI beginning at age 30) and consideration of risk-reducing mastectomy.
• CHEK2 (Checkpoint Kinase 2): Encodes a serine/threonine kinase activated by ATM in response to double-strand breaks. Common truncating mutations (such as 1100delC) confer a 20% to 40% lifetime breast cancer risk (predominantly ER-positive) and modestly elevated colorectal cancer risk. NCCN recommends annual mammography starting at age 40 and consideration of annual breast MRI starting at age 30 to 35.
• ATM (Ataxia-Telangiectasia Mutated): Functions as the master sensor kinase recruiting repair machinery to double-strand breaks. Heterozygous carriers have a 20% to 30% lifetime breast cancer risk (predominantly ER-positive) and elevated pancreatic cancer risk. Homozygous mutations produce classical ataxia-telangiectasia.

---

Indications for Genetic Counseling and Multigene Panel Testing

National Comprehensive Cancer Network (NCCN) clinical practice guidelines outline explicit criteria for referring patients for formal cancer genetic counseling and multigene panel testing:

1. Personal history of breast cancer diagnosed at or before age 50.
2. Personal history of triple-negative breast cancer (TNBC) at any age.
3. Multiple primary breast cancers (synchronous or metachronous bilateral disease).
4. Breast cancer diagnosed at any age with at least one close blood relative diagnosed with breast cancer at or before age 50, epithelial ovarian cancer, pancreatic cancer, or high-risk/metastatic prostate cancer.
5. Personal or family history of male breast cancer at any age.
6. Personal or family history of epithelial ovarian, fallopian tube, or primary peritoneal cancer at any age.
7. Ashkenazi Jewish ancestry in an individual with personal breast, ovarian, or pancreatic cancer at any age.
8. Known pathogenic or likely pathogenic variant in a cancer susceptibility gene in a biological relative.
9. Treatment decisions: HER2-negative breast cancer in which a germline result would determine eligibility for a PARP inhibitor (olaparib or talazoparib).

Testing may also be considered for anyone diagnosed at 65 or younger who meets none of these criteria, and the 2024 ASCO-SSO guideline recommends offering BRCA1/2 testing to all patients newly diagnosed with breast cancer at age 65 or younger.

---

Genetic Counseling, VUS Management, and Legal Protections

Navigating genetic testing requires adherence to ethical, psychological, and legal standards.

The Pre-Test and Post-Test Counseling Framework

• Pre-Test Counseling: Involves constructing a complete pedigree, evaluating prior testing, explaining multi-gene panel testing versus single-site testing, discussing cost and insurance pre-authorization, outlining possible outcomes, and evaluating the patient's psychological readiness to receive potentially actionable or ambiguous results.
• Test Outcomes: Results fall into three discrete categories: Positive (Pathogenic / Likely Pathogenic variant identified; actionable), Negative (True negative if a known familial mutation was tested; uninformative negative if no mutation is found in a family with strong cancer history), or Variant of Uncertain Significance (VUS).

Management of Variants of Uncertain Significance (VUS)

A Variant of Uncertain Significance (VUS) represents a DNA sequence change whose association with disease risk is currently unknown (insufficient population frequency data or functional assay evidence).

Critical Clinical Rule: A VUS must never be treated as a positive result. Prophylactic surgeries (bilateral mastectomy, risk-reducing salpingo-oophorectomy) must never be recommended or performed on the basis of a VUS. Patient surveillance and interventions must be managed strictly according to personal risk factors and objective family cancer history until research reclassifies the variant.

The Genetic Information Nondiscrimination Act (GINA) of 2008

GINA is a federal statute that establishes vital protections against discrimination based on genetic test results or family history of disease:

• What GINA Protects:
  1. Health Insurance: Prohibits group and individual health insurers from using genetic information to deny enrollment, adjust group premiums, or impose pre-existing condition exclusions.
  2. Employment: Prohibits employers (with 15 or more employees) from using genetic information in hiring, firing, job assignments, promotion decisions, or compensation.
• What GINA Does NOT Protect: GINA explicitly does not apply to life insurance, long-term care insurance, or disability insurance. Insurers in these sectors can legally request genetic testing records and deny coverage or increase premiums based on mutation status. Additionally, GINA does not protect active-duty military personnel receiving healthcare through Tricare, the Veterans Health Administration, or employees of small businesses with fewer than 15 workers.